Clinical Trials

Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-503-5944.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.

Search Studies

Trials
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of … This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of Dermatology hopes todevelop a better understanding of skin diseases (meaning the knowledge about how cells in theskin behave and react to medical treatments) among researchers at Northwestern University andother approved researchers. This basic knowledge is expected to help the development of moreeffective patient care and new treatment methods. Eligibility Criteria Consent to have specimens collected as part of a standard of care procedure Have a skin disease diagnosis which researchers want samples of in order to further understand the disease Qualify as a healthy volunteer (a person with no skin disease) Principal Investigator Rangel, Stephanie Marie Location(s) Map it 676 N. St. Clair St. Chicago, IL IRB number STU00009443 More Info Keywords biopsy tissue biorepository dermatology Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Epidermolysis Bullosa Clinical Characterization and Outcomes Database The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, … The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB. Eligibility CriteriaAll candidates with a clinical diagnosis of epidermolysis bullosa are eligible for this study. The subjects can be from any age, male or female without restriction. Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00202682 More Info Keywords Epidermolysis Bullosa Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Wool Clothing for Atopic Dermatitis This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks … This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks or begin with standard garments for 6 weeks and switch to wool garments for a further 6 weeks. Participants will attend follow-up appointments at 3, 6, 9 and 12 weeks where severity of eczema,quality of life, and any side effects will be assessed. Wool clothing and laundry detergent will be provided for the duration of the entire study. Eligibility Criteria Ages 3 months to 5 years with moderate to severe eczema as determined atinitial visit. Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00208730 More Info Keywords eczema atopic dermatitis wool Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Characterization of the microbiome in cutaneous T cell lymphoma The purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL). Eligibility Criteria Be between the ages of 18-89 Be able and willing to provide informed consent You must not have cutaneous t-cell lymphoma (CTCL) You must not be currently pregnant You must not be on or exposed to systemic antibiotics with 4 weeks of beginning study participation Principal Investigator Zhou, Alan Location(s) Map it 676 N. St. Clair St. Chicago, IL IRB number STU00209226 More Info Keywords Cutaneous T-Cell Lymphoma Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age) The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. … The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug). Eligibility Criteria You could be in this study if: You are 6 to 17 years old A doctor has said you have chronic plaque psoriasis You have had chronic plaque psoriasis for at least 6 months You have taken medication for your psoriasis, but it hasn’t worked Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL ClinicalTrials.gov IdentifierNCT03451851IRB number STU00209613 More Info Keywords Chronic Plaque Psoriasis Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who … The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience. Additionally, researchers are interested in: Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed Identifying other types of conditions associated with skin disorders Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes Creating a “Biorepository Specimen Bank” with blood and saliva samples Eligibility Criteria Have a skin condition such as Atopic Dermatitis, Psoriasis, Alopecia, Vitiligo, Hidradenitis Suppurativa and others. You will not be asked to take any medications as part of this study. Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00209616 More Info Keywords Immune-mediated Inflammatory Skin Condition Atopic Dermatitis Psoriasis Alopecia Vitiligo Hidradenitis Suppurativa Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Comparison of disease knowledge in dyads of parents and their adolescents with chronic skin disorders The main goal of this study is to understand how much parents and teenagers know about the teenagers’ chronic skin condition. Eligibility Criteria This study will enroll children ages 12 to 17 years of age with a diagnosis of psoriasis, atopic dermatitis (eczema), or ichthyosis. Both the child and participating parent must speak English. Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00212092 More Info Keywords Psoriasis Atopic Dermatitis Eczema Ichthyosis Email Study Coordinator Phone Copy Study URL to Clipboard Copy
A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTS This study is trying to determine whether an ointment is safe and effective for the treatment of hand-foot skin reaction induced by VEGRF inhibitors. Eligibility CriteriaParticipants must be over the age of 18 and have hand-foot skin reaction after taking anti-cancer medications calls VEGRF inhibitors. Principal Investigator Choi, Jennifer Nam Location(s) Map it 676 N. St. Clair St. Chicago, IL ClinicalTrials.gov IdentifierNCT04088318IRB number STU00211322 More Info Keywords hand-foot skin reaction HFSR Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Impact of immunotherapy-related skin diseases on quality of life The purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey. Eligibility CriteriaParticipants need to be 18 years and older, receiving immunotherapy, and may be experiencing a dermatologic side effect. Principal Investigator Choi, Jennifer Nam Location(s) Map it 676 N. St. Clair St. Chicago, IL IRB number STU00212205 More Info Keywords oncodermatology quality of life survey Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Tape Strip Analysis in Dermatologic Diseases The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples … The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples from a broad range of dermatologic diseases, which may include psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, and other rare conditions, in addition to healthy controls. Eligibility Criteria Have a dermatologic disease such as psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, or other rare skin condition Be a healthy volunteer (someone with no dermatologic disease) Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00213591 More Info Keywords Psoriasis Epidermoysis Bullosa Atopic Dermatitis Ichthyosis Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
A Prospective and Retrospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the Hospital The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.… The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting. Eligibility Criteria Be older than 18 Be admitted to Northwestern Memorial Hospital or evaluated in the Emergency Department for whom an inpatient dermatology consultation is requested. Principal Investigator Nguyen, Cuong Location(s) Map it 251 E. Huron St. Chicago, IL IRB number STU00212714 More Info Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Identifying Druggable Targets of Acanthosis Nigricans via Bulk Transcriptomics This study is being done to understand how Acanthosis Nigricans develops in order to develop targets for drugs to be developed in the future. Participants will be in the study for up to 2 weeks and will provide skin biopsies and blood. Photos and medical history will also be collected.&… This study is being done to understand how Acanthosis Nigricans develops in order to develop targets for drugs to be developed in the future. Participants will be in the study for up to 2 weeks and will provide skin biopsies and blood. Photos and medical history will also be collected. Eligibility CriteriaParticipants must have Acanthosis Nigricans or meet the criteria to participate as a healthy control. Principal Investigator Paller, Amy Location(s) Map it 676 N. St. Clair St. Chicago, IL IRB number STU00214401 More Info Keywords acanthosis nigricans healthy control Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells … The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris. Eligibility Criteria Must be at least 18 years of age Have a confirmed diagnosis of mucosal-dominant pemphigus vulgaris or have a prior positive demoglein 3-ELISA result (a pemphigus vulgaris diagnostic tool) and confirmed by biopsy at the screening visit Have pemphigus vulgaris that has previously been inadequately managed by at least one prior standard therapy Principal Investigator Zhou, Alan Location(s) Map it 676 N. St. Clair St. Chicago, IL ClinicalTrials.gov IdentifierNCT04422912IRB number STU00214626 More Info Keywords Pemphigus vulgaris CAART Email Rangel, Stephanie Marie Phone +1 312 503 5942 Copy Study URL to Clipboard Copy
Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug level"). This is measured by blood tests. Another purpose is to find out if ustekinumab can … The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug level"). This is measured by blood tests. Another purpose is to find out if ustekinumab can cause side effects, which are unexpected or unwanted reactions from taking a drug. Study participation is a maximum of 16 weeks. No study drug will be provided for this study, only study procedures (blood draw, specific vital signs) will be performed. Eligibility Criteria Be between 6-18 years of age with a diagnosis of juvenile psoriatic arthritis Be between 6 to <18 years of age, with a diagnosis of pediatric psoriasis Have started ustekinumab treatment for at least 16 weeks prior to participating and have received 3 or more doses of ustekinumab prior to participating Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00216219 More Info Keywords Juvenile Psoriatic Arthritis Pediatric Psoriasis Ustekinumab Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Irritancy and Allergenicity of Synthetic-Melanin-Based Hair Dye Components The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a compound that is known to cause allergic reactions. This study aims to … The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a compound that is known to cause allergic reactions. This study aims to investigate the possibility of using synthetic melanin as a hair dye as an alternative. Eligibility Criteria Healthy adults ages 18 years or older with skin allergy to PPD Able to list all current medications and medical conditions Capable of giving informed consent. Principal Investigator Gianneschi, Nathan Location(s) Map it 676 N. St. Clair St. Chicago, IL IRB number STU00213915 More Info Keywords Skin Allergy Hair Dye Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.… This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated. Eligibility Criteria Be 2-17 years old Have a clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months Have involvement of plaque psoriasis on at least 3% of the body, excluding the scalp Principal Investigator Paller, Amy Location(s) Map it 225 E. Chicago Ave. Chicago, IL IRB number STU00216645 More Info Keywords Plaque psoriasis Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Investigation of Sleep and Health Outcomes in Women Reporting Normal and Heavy Menses Flow We are interested in understanding how the menstrual cycle and severity of menses (lheavier menstrual flow) affects sleep. Eligibility Criteria Be between the ages of 18 and 50 Pre-menopausal with regular menstrual cycles every 21-35 days Self-report 3 to 7 days of flow in menstruation Have an intact uterus and at least 1 ovary Not currently or soon to be pregnant Not using an IUD (unless copper) Not regularly using sleep aids Principal Investigator Walter, Jessica Location(s) Map it 676 N. St. Clair St. Chicago, IL IRB number STU00215465 More Info Keywords Menstrual Cycle Sleep Menses Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, … The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink. Eligibility Criteria Patient must be 18 years of age or older. Patient must have pathologically confirmed T or NK cell lymphoma. For CTCL, patients with stage IB disease or greater are eligible. Relapse or refractory disease after at least 1 systemic therapy No prior therapy with ruxolitinib Patient must not be pregnant No concurrent illness/disease or other systemic therapies unrelated to T-cell lymphoma Principal Investigator Choi, Jaehyuk Location(s) Map it 676 N. St. Clair St. Chicago, IL ClinicalTrials.gov IdentifierNCT02974647IRB number STU00216438 More Info Keywords Ruxolitinib NK-cell lymphoma T-cell lymphoma CTCL Email Study Coordinator Phone 312 503 5944 Copy Study URL to Clipboard Copy
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL MF) As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment … As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with CTCL. Eligibility Criteria Patient who has a diagnosis of mycosis fungoides (MF). Patient who is between 2-89 years of age. Patient who is willing and able to provide new skin samples via superficial scraping at least one affected and non-affected body site. Principal Investigator Guitart, Joan IRB number STU00217977 More Info Email Lara Landa, Itzel Xiadani Phone Copy Study URL to Clipboard Copy

Clinical Trials

Feinberg Clinical Trials

DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY

Epidermolysis Bullosa Clinical Characterization and Outcomes Database

Wool Clothing for Atopic Dermatitis

Characterization of the microbiome in cutaneous T cell lymphoma

A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age)

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

Comparison of disease knowledge in dyads of parents and their adolescents with chronic skin disorders

A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTS

Impact of immunotherapy-related skin diseases on quality of life

Tape Strip Analysis in Dermatologic Diseases

A Prospective and Retrospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the Hospital

Identifying Druggable Targets of Acanthosis Nigricans via Bulk Transcriptomics

A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris

Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants

Irritancy and Allergenicity of Synthetic-Melanin-Based Hair Dye Components

A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Investigation of Sleep and Health Outcomes in Women Reporting Normal and Heavy Menses Flow

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL MF)